Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC)

被引：0

作者：

Besse, B. ^{[1
]}

Shaw, A. T. ^{[2
]}

Solomon, B. J. ^{[3
]}

Bauer, T. M. ^{[4
]}

Chiari, R. ^{[5
]}

Lin, C-C. ^{[6
]}

Satouchi, M. ^{[7
]}

Clancy, J. S. ^{[8
]}

James, L. P. ^{[9
]}

Abbattista, A. ^{[10
]}

Felip Font, E. ^{[11
]}

机构：

[1] Dept Med Oncol, Gustave Roussy Canc Campus, Villejuif, France

[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[3] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia

[4] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA

[5] Azienda Osped Perugia, Santa Maria della Misericordia Hosp, Med Oncol, Perugia, Italy

[6] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[7] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan

[8] InVentiv Clin, Clin, Princeton, NJ USA

[9] Pfizer Oncol, Global Prod Dev, New York, NY USA

[10] Pfizer Oncol, Global Biometr & Data Management, Milan, Italy

[11] Vall dHebron Inst Oncol, Oncol, Barcelona, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1308PD

引用

页数：2